Please select an option below to help us tailor your newsletter to best suit your content interests!
Dr. Jason Porter talks with OncLive about potential sequencing with antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) for HER2+ #lungcancer. Porter states, “The TKIs are oral medications that target HER2 specifically and do not require intravenous infusion. Given the ongoing COVID-19 pandemic, the utility of outpatient therapy with the TKIs may be preferrable to trastuzumab deruxtecan. However,… Read more »
Portnoy says, “It’s been a long time since we’ve had a breakthrough in small cell lung cancer (#SCLC), and we are finally seeing some real concrete improvements in survival with first-line therapy and with those who have progressed on first line therapy. After years of heartbreak and minimal improvement, we’re beginning to see these breakthroughs… Read more »
Dr. Axel Grothey talks with Targeted Oncology how #HER2 has become an actionable target for #GIcancers and potential HER2-targeted treatments in the field, as well as other interesting studies from the role trastuzumab plays in the GI cancer clinical space. Click to read a transcript of this full interview!
Dr. Jason Porter, one of our incredible Lung Oncology Specialists, recently participated in an OncLive “Institutional Perspectives in Cancer” webinars, which allows attendees to consume and digest data easily and take what they learned back to their clinical practice. Click here to watch the full panel webinar with Jason Porter, MD, Janakiraman Subramanian, MD, Natalie S. Calendar,… Read more »
Our very own, Dr. Noam VanderWalde, participated in the third edition of tipsRo’s new webinar series “Ask the Authors.” Dr. VanderWalde and Dr. Niluja Thiruthaneeswaran, Radiation Oncologist at Crown Princess Mary Cancer Centre In Austrailia, hosted this webinar specifically focused on Geriatric Oncology in Radiotherapy. Click here to review the resources and downloads available from… Read more »
“The management of locally advanced #RectalCancer has grown in both complexity and quality since the first proctectomy. What once was a malignancy with a fairly consistent treatment algorithm for decades, a recent paradigm shift in the care of these patients has led to a more personalized, multidisciplinary approach with variations in timing, sequence, duration, and potential exclusion… Read more »
Axel Grothey, MD, medical oncologist and director of Gastrointestinal Cancer Research at West Cancer Center and Research Institute, discusses the potential utility of trifluridine/tipiracil (TAS-102; Lonsurf) in combination with bevacizumab (Avastin) in metastatic colorectal cancer (mCRC). Currently, TAS-102 is reserved for single-agent use in the third-line setting for patients with mCRC, says Grothey. However, TAS-102… Read more »
Join Dr. Axel Grothey, our Director of GI Cancer Research, on Thursday, May 20 at 7pm ET as he co-hosts an OncLive webinar titled “The Impact of Minimal Residual Disease in Cancer” alongside Tanois Behaii-Saab, MD and Manju George, MVSc PhD. Click here to learn more or register for this event: https://globalmeet.webcasts.com/starthere.jsp…
written by Jason Bolton – Data Editor, Memphis Business Journal Click here to view article on Memphis Business Journal website. Creating a collaborative community of care is an important concept for Dr. Matthew Ballo. In 2014, Ballo was recruited to Memphis to head up the radiation oncology department at West Cancer Center — then called The… Read more »
Regional One Health and West Cancer Center Partner to Provide Cancer Care at Midtown Location Regional One Health and West Cancer Center and Research Institute have partnered to bring exciting changes to the Midtown cancer center. Effective March 1, 2021, the West Cancer Center Midtown location has transitioned to a hospital outpatient department of Regional… Read more »